Digital technologies are beginning to impact clinical trial operations and provide several operational efficiencies. Traditional recruitment methods have struggled to attract study participants with characteristics that reflect real world populations. For example, regulators stress the need for more diverse study populations. New digital technologies may enable more diverse study enrollment, which could help sponsors understand risks associated with new therapies. As such, digital technologies are gaining momentum in the clinical trial community.
Regardless of the technology used, the future of clinical trials depends on the mindset of participants. As more patients get involved, the field may reach a tipping point where the benefits of clinical research are perceived as more widely accessible and acceptable. As a result, former participants may become public relations ambassadors for research. Additionally, as the language of clinical research evolves, more people will understand how trials work. As a result, trials could become nearly ubiquitous in health care settings. For details on Paid Medical Trials, contact a site like www.trials4us.co.uk
Decentralised clinical trials have many advantages over centralised clinical trials. Decentralised trials help increase the pool of potential patients, and can benefit a diverse population as well. They may also benefit those in the early stages of clinical research. It is difficult to find a suitable patient pool, so decentralised trials are an important option.
In the coming decade, the future of clinical trials will focus on treating participants as individuals, rather than just subjects. By treating trial participants as collaborators, companies can gain insight from them. These patients will have access to data visualisations and personalised health reports. This will enable them to carry their experience forward and take greater ownership of their own health. And, these advances are transforming the industry as we know it. There are numerous innovations underway in the field of technology, and companies should take note of these new developments.
In the current context of ageing populations, global disease burdens, and increasing demands on health care systems, clinical trials are under-appreciated and often misunderstood. Meanwhile, the focus on cost and value of medicines has put industry under pressure to innovate faster. With the right transformation, clinical trials can fulfil their role in creating a bright future for humanity.
Open clinical trials will have connected infrastructure, consistent operations, and cooperative stakeholder involvement. Instead of being a “black box,” these trials will break down traditional stakeholder silos and foster speed and consistency. By sharing the foundation, researchers can focus their attention on the science rather than the administrative processes. Many of these elements are already present in the industry today, but more are yet to come as stakeholders adopt greater systems thinking.
